Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioma × olaparib × Clear all

Phase

Phase 2 6 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Breast Neoplasms 8 Small Cell Lung Carcinoma 4 Prostatic Neoplasms 4 Stomach Neoplasms 3 Neoplasms 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Metastatic Castration-Resistant Prostate Cancer 1 Male Urogenital Diseases 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Glioma 1 Genital Neoplasms, Male 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Temozolomide 23 Radiotherapy 10 Bevacizumab 9 Carboplatin 6 pembrolizumab 4 Radiation 4 Nivolumab 4 Irinotecan 4 IL13-PE38 4 Surgical Procedures, Operative 3 Aminolevulinic Acid 3 trametinib 2 temsirolimus 2 dabrafenib 2 abemaciclib 2 Vorinostat 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Magnetic Resonance Spectroscopy 2 Immunotherapy, Adoptive 2 Imatinib Mesylate 2 Erlotinib Hydrochloride 2 Chlorotoxin 2 Cetuximab 2 Cancer Vaccines 2 Biopsy 2 vocimagene amiretrorepvec 1 veliparib 1 trastuzumab deruxtecan 1 trans-sodium crocetinate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03212742 2025-12-04

OLA-TMZ-RTE-01

Centre Francois Baclesse

Phase 1/2 Active not recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡